文献速递药物不良反应与药物警戒

法国药物警戒公共体系与COVID-19大流行

French Pharmacovigilance Public System and COVID-19 Pandemic.
PubMed 文献 · Drug Saf · 2020-12-28

本文介绍COVID-19大流行期间法国公共药物警戒活动。因早期无已知有效药物,多种候选药物被提出。COVID-19本身是混杂因素,可致多器官损伤包括心脏和肾脏,但不良反应报告数据质量、临床医生反馈及时性及区域药物警戒中心网络的实时药理学与医学分析使相关安全信号得以快速识别,法国国家药品管理局因此能很早就验证数据并传达发现。这种基于病例报告医学与药理学评估的去中心化组织在此独特而严峻的卫生紧急事件中被证明高效且响应迅速。

要点

  • COVID-19可致多器官损伤,是药物不良反应评价中的固有混杂因素。
  • 区域药物警戒中心网络的实时药理学与医学分析有助于快速识别安全信号。
  • 去中心化药物警戒组织在卫生紧急事件中表现出高效与响应性。

核心结论

  • 法国去中心化的公共药物警戒体系在COVID-19大流行这一独特卫生紧急事件中被证明高效且响应迅速。

研究设计与样本

  • 本文为短文,介绍COVID-19大流行期间法国公共药物警戒活动,未报告研究设计与样本量。

主要发现

  • COVID-19本身是混杂因素,因其可致多器官损伤包括心脏和肾脏。
  • 不良反应报告数据质量、临床医生反馈及时性及区域药物警戒中心网络的实时药理学与医学分析使相关安全信号得以快速识别。
  • 法国国家药品管理局因此能很早就验证数据并传达发现。

临床怎么用

  • 临床药学智能体医生在评价药物不良反应时需考虑COVID-19多器官损伤的混杂影响。
  • 可借鉴区域药物警戒网络实时药理学与医学分析的模式快速识别安全信号。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The current COVID-19 pandemic is an exceptional health situation including for drug use. As there was no known effective drug for COVID-19 at the beginning of the pandemic, different candidates were proposed. In this short article, we present the French public pharmacovigilance activities during this health crisis. Although COVID-19 is a confounding factor per se, owing to its potential for multi-organ damage including the heart and kidney, the quality of the transmitted data in adverse drug reaction reports, the timeliness of feedback from clinicians, and the real-time pharmacological and medical analysis by the French network of the regional pharmacovigilance centers made it possible to swiftly identify relevant safety signals. The French National Agency of Medicine was thus able to validate the data and convey their findings very early. This decentralized organization based on medical and pharmacological evaluation of case reports has proven to be efficient and responsive in this unique and challenging healthcare emergency.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Grandvuillemin A, Drici MD, Jonville-Bera AP, et al. French Pharmacovigilance Public System and COVID-19 Pandemic. Drug Saf. 2020. PMID: 33372244. doi:10.1007/s40264-020-01034-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。